Literature DB >> 8411221

Comparison of single and combination drug treatment strategies in experimental brain trauma.

A I Faden1.   

Abstract

Effects of single-drug and combination drug treatments were examined in a model of lateral fluid percussion-induced traumatic brain injury (TBI) in rats. Treatments included the opioid receptor antagonist nalmefene, the thyrotropin releasing hormone (TRH) analog YM14673, the noncompetitive N-methyl-D-aspartate (NMDA) antagonist dextrorphan, nalmefene + dextrorphan, YM14673 + nalmefene, YM14673 + dextrorphan, and equal volume saline. Single-dose treatment with nalmefene, YM14673, or dextrorphan at 30 min after trauma each significantly improved behavioral recovery at two weeks as compared with vehicle-treated controls, confirming earlier studies with these agents. No combination treatment was superior to treatment with the most effective individual drug alone. Combination treatment with the TRH analog and the NMDA antagonist resulted in significantly less effectiveness than treatment with either drug alone. These findings indicate the need for preclinical studies to examine potential drug-drug interactions in the treatment of central nervous system (CNS) trauma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411221     DOI: 10.1089/neu.1993.10.91

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  14 in total

1.  Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT1A receptor agonist buspirone after experimental traumatic brain injury.

Authors:  Anthony E Kline; Adam S Olsen; Christopher N Sozda; Ann N Hoffman; Jeffrey P Cheng
Journal:  J Neurotrauma       Date:  2012-05-21       Impact factor: 5.269

2.  Fluid-percussion-induced traumatic brain injury model in rats.

Authors:  Shruti V Kabadi; Genell D Hilton; Bogdan A Stoica; David N Zapple; Alan I Faden
Journal:  Nat Protoc       Date:  2010-08-19       Impact factor: 13.491

Review 3.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

4.  Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury.

Authors:  A G Yakovlev; S M Knoblach; L Fan; G B Fox; R Goodnight; A I Faden
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

Review 5.  Animal models of head trauma.

Authors:  Ibolja Cernak
Journal:  NeuroRx       Date:  2005-07

6.  An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro.

Authors:  Michael C Veronesi; Michael Yard; James Jackson; Debomoy K Lahiri; Michael J Kubek
Journal:  Brain Res       Date:  2006-11-27       Impact factor: 3.252

7.  The Therapeutic Efficacy of Environmental Enrichment and Methylphenidate Alone and in Combination after Controlled Cortical Impact Injury.

Authors:  Jacob B Leary; Corina O Bondi; Megan J LaPorte; Lauren J Carlson; Hannah L Radabaugh; Jeffrey P Cheng; Anthony E Kline
Journal:  J Neurotrauma       Date:  2016-05-09       Impact factor: 5.269

Review 8.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

9.  Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.

Authors:  Anthony E Kline; Rose L McAloon; Kate A Henderson; Utsav K Bansal; Bhaskar M Ganti; Rashid H Ahmed; Robert B Gibbs; Christopher N Sozda
Journal:  J Neurotrauma       Date:  2010-10-28       Impact factor: 5.269

Review 10.  Multifunctional drug treatment in neurotrauma.

Authors:  Bogdan Stoica; Kimberly Byrnes; Alan I Faden
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.